TDOC Partners With TytoCare to Expand At-Home Exam Capabilities
Teladoc Health deepens its virtual care reach by adding TytoCare's at-home exam tech to Primary360 and 24/7 Care starting in 2026.
Cathie Wood Bets Big On This Peter Thiel-Backed Coinbase Rival As Bitcoin Crashes Below $91,000 - Grayscale Bitcoin Mini Trust ( BTC ) Common units of fractional undivided beneficial interest ( ARCA:BTC )
On Monday, Cathie Wood-led Ark Invest executed significant trades involving Bullish ( NYSE:BLSH ) , Reddit Inc. ( NYSE:RDDT ) , and Pinterest Inc. ( NYSE:PINS ) .
Ensign Group Shares Decline 2.2% Despite Q3 Earnings Beat
ENSG shares slip 2.2% despite Q3 earnings and revenues topping estimates, as higher service and rent costs weigh on results.
VP At Veracyte Sells $449K Of Stock - Veracyte ( NASDAQ:VCYT )
Jonathan Wygant, VP at Veracyte ( NASDAQ:VCYT ) , executed a substantial insider sell on November 12, according to an SEC filing. What Happened: A Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday outlined that Wygant executed a sale of 10,920 shares of Veracyte with ...
Encompass Health Shares Down 8% Despite Q3 Earnings & Revenue Beat
EHC shares fall 8% after Q3 results, as higher costs offset revenue gains, bed expansions and an upbeat 2025 outlook.
VCYT Stock Gains on Q3 Earnings and Revenue Beat, '25 View Up
Veracyte surges 27.5% after Q3 earnings and revenues beat estimates, driven by strong Decipher and Afirma test growth.
Tenet Healthcare Shares Down 5% Despite Q3 Earnings Beat
THC's Q3 profit beats estimates on higher revenues and strong segment growth, but rising costs drag shares lower.
Pediatrix Medical Q3 Earnings Beat Estimates on Declining Expenses
MD's Q3 profit tops on lower expenses and improved patient acuity, driving earnings past estimates despite softer revenues.
Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday - Babcock & Wilcox ( NYSE:BW ) , Digital Turbine ( NASDAQ:APPS )
U.S. stocks were higher, with the Nasdaq Composite gaining more than 200 points on Wednesday. Shares of Johnson Controls International PLC ( NYSE:JCI ) rose sharply during Wednesday's session after the company reported fourth-quarter results that topped analyst estimates on both earnings and ...
Veracyte ( VCYT ) Q3 Earnings and Revenues Beat Estimates
Veracyte (VCYT) delivered earnings and revenue surprises of +59.38% and +5.50%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
EW Stock Gains on Q3 Earnings and Revenue Beat, Margins Crash
Edwards Lifesciences Q3 earnings and sales beat estimates on robust TAVR and TMTT growth, though margins take a sharp hit.
ALGN Stock Up on Q3 Earnings and Revenue Beat, Margins Crash
Align Technology jumps 15% after Q3 earnings and revenues beat estimates, though steep margin declines weigh on results.
CHE Stock Falls on Q3 Earnings and Revenue Miss, Margins Crash
Chemed's Q3 miss sends shares lower as shrinking margins and weaker EPS overshadow steady revenue gains from VITAS and Roto-Rooter.
LH Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down
Labcorp's Q3 earnings beat forecasts and margins improve, but a trimmed 2025 sales outlook sends shares down.
Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer - Artelo Biosciences ( NASDAQ:ARTL )
SOLANA BEACH, Calif., Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Artelo Biosciences, Inc. ( NASDAQ:ARTL ) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today ...
ITGR Shares Down Despite Q3 Earnings & Revenues Beat Estimates
Integer Holdings posts strong Q3 results with earnings and revenue beat, but shares plunge on a softer 2026 growth outlook.
ISRG Stock Gains on Q3 Earnings & Revenue Beat, Gross Margin Declines
Intuitive Surgical's shares jump 17% after Q3 earnings and revenues beat expectations, fueled by surging da Vinci 5 placements and strong global procedure growth.
Boston Scientific Beats on Q3 Earnings, Raises 2025 View, Stock Up
BSX posts strong Q3 with 19% EPS growth, lifts 2025 sales and EPS outlook as shares edge higher.
Thermo Fisher's Q3 Earnings & Revenues Top Estimates, Stock Climbs
TMO delivers robust Q3 results, fueled by margin growth, new launches and AI-focused strategic initiatives.
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Quest Diagnostics Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
DGX posts a strong Q3 with revenues and EPS beating estimates, higher margins and an upbeat full-year outlook.
Veracyte ( VCYT ) Crossed Above the 20-Day Moving Average: What That Means for Investors
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Abbott's Q3 Earnings Meet Estimates, Revenues Up Y/Y, Stock Climbs
ABT's Q3 earnings meet expectations as revenues climb 6.9% year over year, driven by double-digit gains in Medical Devices.
This Top Medical Stock is a #1 ( Strong Buy ) : Why It Should Be on Your Radar
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
If You Invested $1000 in Veracyte a Decade Ago, This is How Much It'd Be Worth Now
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Why Veracyte ( VCYT ) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership
TEM accelerates its healthcare edge with Paige, Deep 6 AI, and Ambry Genetics acquisitions, expanding data, tech and clinical reach.
Is the Options Market Predicting a Spike in Veracyte Stock?
Investors need to pay close attention to VCYT stock based on the movements in the options market lately.
Here's Why Veracyte ( VCYT ) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Veracyte ( VCYT ) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up
Veracyte Q2 earnings and revenues beat estimates, fueled by Decipher and Afirma growth, sending shares up over 15%.
Helix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer Care
Collaboration brings whole-exome based hereditary cancer insights to urologists and their patients by offering it alongside Veracyte's Decipher Prostate Test
Veracyte ( VCYT ) Q2 Revenue Jumps 14%
Veracyte ( NASDAQ:VCYT ) , a leader in advanced cancer diagnostics, reported results for Q2 2025 on August 6, 2025. The headline news: the company outperformed expectations on both revenue and profitability, driven by strong expansion in its core prostate cancer genomic testing platform.
Veracyte ( VCYT ) Tops Q2 Earnings and Revenue Estimates
Veracyte (VCYT) delivered earnings and revenue surprises of +41.94% and +7.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Cathie Wood's $15M Crypto Bet: Sells Bitcoin King Block, Doubles Down On Ethereum Giant Bitmine Immersion - Grayscale Ethereum Mini Trust ( ETH ) Common units of fractional undivided beneficial interest ( ARCA:ETH )
On Tuesday, Cathie Wood-led Ark Invest executed significant trades, focusing on Bitmine Immersion Technologies Inc. BMNR and Block Inc. XYZ. These trades reflect Ark's strategic positioning in the market amidst evolving financial landscapes.
Cathie Wood Goes On A $20M Bitmine Immersion Bargain Hunt As Ark Trims Robinhood And Palantir Stakes - ARK Fintech Innovation ETF ( BATS:ARKF )
On Monday, Cathie Wood-led Ark Invest made significant trades, including a notable purchase of Bitmine Immersion Technologies Inc. ( BMNR ) shares. The investment firm also increased its holdings in Alphabet Inc. GOOG and NVIDIA Corp NVDA, while reducing its stake in Robinhood Markets Inc.
Veracyte ( VCYT ) Soars 7.0%: Is Further Upside Left in the Stock?
Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Should You Continue to Hold Veracyte Stock in Your Portfolio Now?
VCYT's Decipher growth and strong cash position bolster its outlook, but Biopharma headwinds and macro risks loom.
Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches
TEM expands its precision medicine arsenal with AI-powered tools, liquid biopsy tech and genome sequencing.
Cathie Wood Doubles Down On Shopify, Buys The Dip - Dumps $4.6 Million Worth Of Robinhood Stock At Peak - ARK Fintech Innovation ETF ( BATS:ARKF ) , ARK Innovation ETF ( BATS:ARKK )
Cathie Wood-led Ark Invest made notable trades on Wednesday, focusing on Shopify Inc. SHOP and Robinhood Markets Inc. HOOD.
Cathie Wood Drops $6.5 Million On SHOP And ABNB, Betting You Won't Stop Shopping Or Traveling - ARK Fintech Innovation ETF ( BATS:ARKF ) , Airbnb ( NASDAQ:ABNB )
Cathie Wood-led Ark Invest made significant trades on Tuesday, spotlighting its strategic acquisitions of Shopify Inc. SHOP and Airbnb Inc. ABNB. These trades reflect Ark's continued interest in high-growth technology and e-commerce sectors.
Cathie Wood Dumps $1.8 Million In Coinbase Stock As Bitcoin Nears $110K All-Time High - ARK Fintech Innovation ETF ( BATS:ARKF )
On Monday, Cathie Wood-led Ark Invest made a notable move by selling shares of Coinbase Global Inc. COIN across its ETFs. This decision comes as Coinbase has been riding a wave of optimism in the cryptocurrency market, fueled by Bitcoin's BTC/USD ascent and Coinbase's recent inclusion in the S&P ...
Veracyte ( VCYT ) Down 13.6% Since Last Earnings Report: Can It Rebound?
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cathie Wood Drops $373 Million On Circle's 168% Rally, Dumps Coinbase And Crypto Holdings - Is Ark Ditching Bitcoin for Stablecoins? - ARK 21Shares Bitcoin ETF Common Shares of Beneficial Interests ( BATS:ARKB )
Cathie Wood's Ark Invest made a blockbuster purchase of Circle Internet Group CRCL shares on Thursday, marking a significant move in the evolving digital assets landscape. The bold acquisition came as Ark simultaneously reshuffled its cryptocurrency stock portfolio, reducing exposure to other ...
Cathie Wood Dumps Another $5.2 Million Of Palantir Stock Amid Trump Administration-Linked Surveillance Controversy - ARK Innovation ETF ( BATS:ARKK ) , Palantir Technologies ( NASDAQ:PLTR )
On Wednesday, Cathie Wood's Ark Invest made a significant move by selling a substantial number of shares in Palantir Technologies Inc. PLTR. This decision comes amidst a brewing controversy surrounding the company's alleged involvement in a surveillance program.
Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally?
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests in the first quarter of 2025.
